170900.KS

Dong-A ST Co., Ltd. [170900.KS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

170900.KS Stock Summary

EPS has been increasing for the past 3 quarters (Quarter statements)

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 years (Yearly statements)

170900.KS has less than 1 year of cash runway

Top 10 Correlated Stocks

170900.KS

In the News

170900.KS Financial details

Company Rating

Strong Buy

Market Cap

540.37B

Income

20.49B

Revenue

634.16B

Book val./share

6401.41

Cash/share

Dividend

Dividend %

Employees

1.65K

Optionable

Shortable

Yes

Earnings

06 Feb 2023

P/E

330.18

Forward P/E

PEG

-35.15

P/S

10.67

P/B

10.04

P/C

P/FCF

-192.15

Quick Ratio

Current Ratio

2.49

Debt / Equity

LT Debt / Equity

EPS (TTM)

194.74

EPS next Y

EPS next Q

EPS this Y

-96.2%

EPS next Y

EPS next 5Y

EPS last 5Y

NAN%

Revenue last 5Y

1.34%

Revenue Q/Q

-1%

EPS Q/Q

611.88%

SMA20

3.04%

SMA50

3.72%

SMA100

14.59%

Inst Own

Inst Trans

ROA

ROE

ROC

0.02%

Gross Margin

49%

Oper. Margin

Profit Margin

Payout

Shs Outstand

8.61M

Shs Float

4.74M

Target Price

52W Range

46176.47-69500.0

52W High

-7.48%

52W Low

+39.25%

RSI

59.79

Rel Volume

0.69

Avg Volume

8.31K

Volume

5.74K

Perf Week

4.21%

Perf Month

5.58%

Perf Quarter

6.81%

Perf Half Y

7.35%

Beta

0.951462

Volatility

546.23%, 1374.76%

Prev Close

-0.16%

Price

64300

Change

-0.77%

170900.KS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31
Revenue per share	65.77K	67.24K	72.56K	69.53K	5.66K
Net income per share	-639.39	949.09	8.4K	3.21K	122.18
Operating cash flow per share	6.07K	5.94K	6.67K	3.2K	470.68
Free cash flow per share	4.7K	4.91K	4.45K	-1.79K	-296.15
Cash per share	22.93K	25.94K	28.02K	30.43K	2.9K
Book value per share	68.87K	68.66K	76.54K	76.09K	6.26K
Tangible book value per share	67.33K	67.33K	74.67K	73.64K	5.89K
Share holders equity per share	68.87K	68.66K	76.54K	76.09K	6.26K
Interest debt per share	22.39K	25.72K	25.41K	25.13K	2.92K
Market cap	1033.72B	843.84B	805.02B	696.17B	6849.9B
Enterprise value	1022.88B	835.87B	787.14B	754.66B	6955.88B
P/E ratio	-191.59	105.36	11.35	25.69	534.47
Price to sales ratio	1.86	1.49	1.31	1.19	11.55
POCF ratio	20.18	16.83	14.31	25.75	138.74
PFCF ratio	26.08	20.37	21.46	-46.02	-220.49
P/B Ratio	1.78	1.46	1.25	1.08	10.44
PTB ratio	1.78	1.46	1.25	1.08	10.44
EV to sales	1.84	1.47	1.29	1.29	11.73
Enterprise value over EBITDA	46.61	19.46	6.72	12.91	184.68
EV to operating cash flow	19.97	16.67	13.99	27.92	140.88
EV to free cash flow	25.8	20.17	20.99	-49.89	-223.91
Earnings yield	-0.01	0.01	0.09	0.04	0
Free cash flow yield	0.04	0.05	0.05	-0.02	0
Debt to equity	0.1	0.12	0.18	0.24	0.24
Debt to assets	0.35	0.39	0.36	0.35	0.41
Net debt to EBITDA	-0.49	-0.19	-0.15	1	2.81
Current ratio	1.88	1.59	2.1	3.13	1.93
Interest coverage	2.79	5.76	7.48	6.55	2.78
Income quality	-9.5	6.26	0.79	1	3.85
Dividend Yield	0	0.01	0.01	0.01	0
Payout ratio	-0.78	0.53	0.12	0.31	0.66
Sales general and administrative to revenue	0.1	0.08	0.07	0.06	0.07
Research and developement to revenue	0.14	0.13	0.12	0.13	0.14
Intangibles to total assets	0.01	0.01	0.02	0.02	0.03
Capex to operating cash flow	-0.23	-0.17	-0.33	-1.56	-1.63
Capex to revenue	-0.02	-0.02	-0.03	-0.07	-0.14
Capex to depreciation	-0.53	-0.43	-0.91	-2.11	-4.03
Stock based compensation to revenue	0	0	0	0	0
Graham number	31.48K	38.29K	120.3K	74.15K	4.15K
ROIC	0.04	0.06	0.07	0.04	0.02
Return on tangible assets	-0.01	0.01	0.07	0.03	0.01
Graham Net	-8.98K	-11.72K	-8.2K	-3.5K	-980.16
Working capital	193.25B	157.5B	237.2B	314.53B	255.46B
Tangible asset value	568.19B	568.16B	630.09B	621.37B	617.97B
Net current asset value	94.27B	57.18B	90.4B	123.67B	71.39B
Invested capital	0.31	0.36	0.32	0.32	0.46
Average receivables	0	0	0	0	0
Average payables	31.05B	30.23B	34.76B	31.54B	33.77B
Average inventory	101.56B	103.83B	109.57B	104.56B	104.58B
Days sales outstanding	0	0	0	0	0
Days payables outstanding	40.56	38.5	46.15	38.07	43.89
Days of inventory on hand	130.77	137.27	139.25	126.21	127.53
Receivables turnover	0	0	0	0	0
Payables turnover	9	9.48	7.91	9.59	8.32
Inventory turnover	2.79	2.66	2.62	2.89	2.86
ROE	-0.01	0.01	0.11	0.04	0.02
Capex per share	-1.37K	-1.03K	-2.22K	-5K	-766.83

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric	2021-06-30	2021-09-30	2021-12-31	2022-06-30	2022-09-30
Revenue per share	17.48K	18K	1.45K	1.55K	1.54K
Net income per share	742.53	1.37K	-54.7	28.69	204.24
Operating cash flow per share	2.51K	2.4K	15.98	55.76	241.06
Free cash flow per share	329.37	14.48	-265.11	-159.02	88.34
Cash per share	28.66K	40.21K	2.89K	0	0
Book value per share	75.41K	77.44K	6.24K	6.2K	6.4K
Tangible book value per share	71.93K	73.25K	5.87K	6.2K	6.4K
Share holders equity per share	75.41K	77.44K	6.24K	6.2K	6.4K
Interest debt per share	24.45K	35.55K	2.86K	13.02	81.74
Market cap	725.7B	634.56B	7533.47B	6134.09B	5239.76B
Enterprise value	751.69B	726.42B	7639.44B	6134.09B	5239.76B
P/E ratio	28.96	13.74	-327.24	508.02	60.96
Price to sales ratio	4.92	4.18	49.26	37.56	32.41
POCF ratio	34.28	31.33	4.48K	1.05K	206.59
PFCF ratio	261.11	5.19K	-270.07	-366.62	563.73
P/B Ratio	1.14	0.97	11.48	9.41	7.78
PTB ratio	1.14	0.97	11.48	9.41	7.78
EV to sales	5.1	4.78	49.96	37.56	32.41
Enterprise value over EBITDA	69.06	42.96	-2.38K	1.08K	168.92
EV to operating cash flow	35.51	35.86	4.54K	1.05K	206.59
EV to free cash flow	270.46	5.94K	-273.87	-366.62	563.73
Earnings yield	0.01	0.02	0	0	0
Free cash flow yield	0	0	0	0	0
Debt to equity	0.16	0.27	0.24	0	0
Debt to assets	0.36	0.42	0.41	0.44	0.44
Net debt to EBITDA	2.39	5.43	-32.96	0	0
Current ratio	2.2	2.2	1.93	2.24	2.49
Interest coverage	0	0	0	3.21	1.7
Income quality	3.38	1.75	-0.29	1.94	1.18
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.07	0.07	0.07	0.47	0.42
Research and developement to revenue	0.12	0.13	0.15	0	0
Intangibles to total assets	0.03	0.03	0.03	0	0
Capex to operating cash flow	-0.87	-0.99	-17.59	-3.85	-0.63
Capex to revenue	-0.12	-0.13	-0.19	-0.14	-0.1
Capex to depreciation	-3.7	-4.07	-5.87	-4.32	-3.08
Stock based compensation to revenue	0	0	0	0	0
Graham number	35.49K	48.82K	2.77K	2K	5.42K
ROIC	0.01	0.01	-0.01	0	0.02
Return on tangible assets	0.01	0.01	-0.01	0	0.02
Graham Net	-7.24K	-10.51K	-977.21	-4.96K	-5.02K
Working capital	251.11B	315.78B	255.46B	308.91B	342.65B
Tangible asset value	606.99B	618.12B	617.97B	0	0
Net current asset value	104.87B	95.26B	71.39B	37.48B	44.27B
Invested capital	0.32	0.46	0.46	0	0
Average receivables	0	0	0	0	0
Average payables	0	0	0	0	0
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	34.64	40.56	40.43	0	0
Days of inventory on hand	126.14	133.08	117.47	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	2.6	2.22	2.23	0	0
Inventory turnover	0.71	0.68	0.77	0	0
ROE	0.01	0.02	-0.01	0	0.03
Capex per share	-2.18K	-2.39K	-281.1	-214.78	-152.72

170900.KS Frequently Asked Questions

What is Dong-A ST Co., Ltd. stock symbol ?

Dong-A ST Co., Ltd. is a KR stock and trading under the symbol 170900.KS

What is Dong-A ST Co., Ltd. stock quote today ?

Dong-A ST Co., Ltd. stock price is $64300 today.

Is Dong-A ST Co., Ltd. stock public?

Yes, Dong-A ST Co., Ltd. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 8.31K
Market Capitalization 540.37B
Employee 1.65K
CEO Mr. Min-Young Kim
Headquarters Seoul,KR
IPO Date 2013-04-05
Website https://www.donga-st.com

Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products and medical devices worldwide. It offers various ethical drugs, including Closerin for active pulmonary and extra-pulmonary tuberculosis; Dulastin and Leucostim for neutropenia in patients receiving myelosuppressive chemotherapy; Eporon for anemia associated with chronic renal failure; Gemcit for non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin for infertility and annovulation; Growtropin II for growth failure due to an inadequate secretion of growth hormone and idiopathic short stature; Mainta for non-small cell lung cancer and malignant pleural mesothelioma; Monotaxel for breast, non-small cell lung, prostate, head, and neck cancers, as well as gastric adenocarcinoma; Motilitone for use in functional dyspepsia treatment; Stillen for the treatment of gastritis; Suganon for diabetes treatment; Terizidone for active pulmonary and extra-pulmonary tuberculosis; and Zydena for erectile dysfunction treatment. The company also provides licensed-in and licensed-out drugs; and medical devices, which cover high technology medical devices, custom made products, and sets of artificial cardiac circuits for use in open-heart surgery. Dong-A ST Co., Ltd. was founded in 1932 and is headquartered in Seoul, South Korea.